167 related articles for article (PubMed ID: 15897698)
1. Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections.
Carmignani G; De Rose AF; Olivieri L; Salvatori E; Rosignoli MT; Dionisio P
Urol Int; 2005; 74(4):326-31. PubMed ID: 15897698
[TBL] [Abstract][Full Text] [Related]
2. Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial.
Chen Y; Yang H; Lu G; Wu X; Huang W; Wu Y; Lv X; Wu G; Zhang G; Li Q; Sun Y
Chemotherapy; 2012; 58(3):249-56. PubMed ID: 22890091
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis.
Grassi C; Salvatori E; Rosignoli MT; Dionisio P;
Respiration; 2002; 69(3):217-22. PubMed ID: 12097764
[TBL] [Abstract][Full Text] [Related]
5. Comparison of three-day temafloxacin with seven-day ciprofloxacin treatment of urinary tract infections in women.
Stein GE; Philip E
J Fam Pract; 1992 Feb; 34(2):180-4. PubMed ID: 1310715
[TBL] [Abstract][Full Text] [Related]
6. Prulifloxacin.
Keam SJ; Perry CM
Drugs; 2004; 64(19):2221-34; discussion 2235-6. PubMed ID: 15456336
[TBL] [Abstract][Full Text] [Related]
7. Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis.
Cazzola M; Salvatori E; Dionisio P; Allegra L
Pulm Pharmacol Ther; 2006; 19 Suppl 1():30-7. PubMed ID: 16359895
[TBL] [Abstract][Full Text] [Related]
8. Lomefloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections: a multicenter study.
Pisani E; Bartoletti R; Trinchieri A; Rizzo M
J Chemother; 1996 Jun; 8(3):210-3. PubMed ID: 8808718
[TBL] [Abstract][Full Text] [Related]
9. Prulifloxacin: a new antibacterial fluoroquinolone.
Prats G; Rossi V; Salvatori E; Mirelis B
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):27-41. PubMed ID: 16441207
[TBL] [Abstract][Full Text] [Related]
10. Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections.
Lipsky BA; Miller B; Schwartz R; Henry DC; Nolan T; McCabe A; Magner DJ; Talbot GH
Clin Ther; 1999 Apr; 21(4):675-90. PubMed ID: 10363733
[TBL] [Abstract][Full Text] [Related]
11. Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections.
Naber KG; Allin DM; Clarysse L; Haworth DA; James IG; Raini C; Schneider H; Wall A; Weitz P; Hopkins G; Ankel-Fuchs D
Int J Antimicrob Agents; 2004 Jun; 23(6):596-605. PubMed ID: 15194131
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
Gualco L; Schito AM; Schito GC; Marchese A
Int J Antimicrob Agents; 2007 Jun; 29(6):679-87. PubMed ID: 17363225
[TBL] [Abstract][Full Text] [Related]
13. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection.
Iravani A; Klimberg I; Briefer C; Munera C; Kowalsky SF; Echols RM
J Antimicrob Chemother; 1999 Mar; 43 Suppl A():67-75. PubMed ID: 10225575
[TBL] [Abstract][Full Text] [Related]
14. Rufloxacin once daily versus ciprofloxacin twice daily in the treatment of patients with acute uncomplicated pyelonephritis.
Bach D; van den Berg-Segers A; Hübner A; van Breukelen G; Cesana M; Plétan Y
J Urol; 1995 Jul; 154(1):19-24. PubMed ID: 7776420
[TBL] [Abstract][Full Text] [Related]
15. [Maxaquin and ciprofloxacin in the treatment of complicated and recurrent urinary infections in adults].
Savitskaia KI; Trapeznikova MF; Nekhorosheva AG; Solodilova OE; Nasonov VN; Dutov VV; Kalinin VN; Shanina AG; Rusanova EV
Klin Med (Mosk); 1994; 72(2):38-42. PubMed ID: 8015241
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis.
Cox CE; Marbury TC; Pittman WG; Brown GL; Auerbach SM; Fox BC; Yang JY
Clin Ther; 2002 Feb; 24(2):223-36. PubMed ID: 11911553
[TBL] [Abstract][Full Text] [Related]
17. Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections.
Rafailidis PI; Polyzos KA; Sgouros K; Falagas ME
Int J Antimicrob Agents; 2011 Apr; 37(4):283-90. PubMed ID: 21300527
[TBL] [Abstract][Full Text] [Related]
18. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Roveta S; Schito AM; Marchese A; Schito GC
Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467
[TBL] [Abstract][Full Text] [Related]
19. Once-daily fleroxacin versus twice-daily ciprofloxacin in the treatment of complicated urinary tract infections.
Frankenschmidt A; Naber KG; Bischoff W; Kullmann K
J Urol; 1997 Oct; 158(4):1494-9. PubMed ID: 9302150
[TBL] [Abstract][Full Text] [Related]
20. Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis.
Blasi F; Schaberg T; Centanni S; Del Vecchio A; Rosignoli MT; Dionisio P
Pulm Pharmacol Ther; 2013 Oct; 26(5):609-16. PubMed ID: 23538168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
